SCHEMBL6476647

SCHEMBL6476647

CCOP(=O)(O)CC(=O)c1cccc(Cn2cccc2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.40
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
CYP19A1 P11511 7/20 0.38
AGTR2 P50052 1/20 0.36
LMNA P02545 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MRGPRX4 Q96LA9 2/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
NFKB1 P19838 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MAPK1 P28482 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5734228 0.84 CYP4F2 (0.42) LMNASMN1; SMN2MRGPRX4CYP4F2CYP4A11
SCHEMBL27660195 0.82 CYP19A1 (0.44) HTTHDAC1HDAC6CYP19A1AGTR2
SCHEMBL5733025 0.82 KAT6A (0.43) LMNASMN1; SMN2MRGPRX4CYP4F2CYP4A11
SCHEMBL5734543 0.81 LMNA (0.42) LMNASMN1; SMN2MRGPRX4TP53PKM
SCHEMBL6476639 0.81 POLB (0.42) HTTHDAC1HDAC6CYP19A1AGTR2
SCHEMBL27660197 0.80 HDAC1 (0.41) HTTHDAC1HDAC6CYP19A1AGTR2
SCHEMBL5732716 0.78 KDM4E (0.45) LMNANPC1RAB9APOLB
SCHEMBL5733074 0.78 L3MBTL1 (0.47) LMNASMN1; SMN2NPC1RAB9AMAPK1
SCHEMBL5732744 0.77 MRGPRX4 (0.56) HTTLMNASMN1; SMN2MRGPRX4TP53
SCHEMBL5734341 0.76 RAB9A (0.44) HTTLMNASMN1; SMN2MRGPRX4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900336-B2 8-aza-11-deoxy prostaglandin analogues SYNTEX (U.S.A.) LLC (US) 2005-05-31 US disclosed
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction SYNTEX (U.S.A.) LLC 2003-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120079-A1 Such as 7-((R)-2-((E)-3-(3-Benzyl-phenyl)-3-hydroxy-propenyl)-5-oxo-pyrrolidin-1-yl)-heptanoic acid; side effects reduction PTGER4, FFAR4, PTGER1 HTT 1724/4885HDAC1 1869/4885HDAC6 3196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.